Lexaria Bioscience Corp. - רווח למניה לשנה מתגלגלת LEXX

The year-over-year EPS (TTM) history for Lexaria Bioscience (LEXX) demonstrates profit dynamics where the indicator reaches 46.70. Lexaria Bioscience (LEXX) is optimizing drug transportation and reducing raw material costs to maintain profitability. The company is currently seeking a major licensee for its patents without mergers, monetizing the DehydraTECH system through partnerships with beverage and medical manufacturers.

Investors must filter out earnings volatility risks by evaluating the trailing twelve-month (TTM) year-over-year (YoY) EPS growth to determine the business's sensitivity to market shocks. For Lexaria Bioscience (LEXX), whose success depends on the licensing of drug delivery systems and partnerships with pharma behemoths, this indicator confirms operational resilience and the fundamental reliability of the model during clinical trial periods.